Table 3 of Yang, Mol Vis 2011; 17:3088-3096.

Table 3. Association between vascular endothelial growth factor (VEGF) polymorphisms and risk of diabetic retinopathy in patients with type 2 diabetes mellitus.


SNP		 Location
of SNPs
Genotype		 Crude OR
(95% CI)		 Adjusted OR
(95% CI)		 p
(Wald's test)
rs699947 Promoter CC 1 1  
    CA 1.14 (0.69, 1.91) 1.04 (0.59, 1.85) 0.89
    AA 3.98 (1.38, 11.42) 3.54 (1.12, 11.19) 0.031
rs833061 Promoter TT 1 1  
    CT 1.10(0.66, 1.84) 1.00 (0.56, 1.79) 0.99
    CC 3.99 (1.39, 11.46) 3.72 (1.17, 11.85) 0.026
rs13207351 Promoter GG 1 1  
    AG 1.08 (0.64, 1.81) 0.98 (0.55, 1.74) 0.95
    AA 4.07 (1.43, 11.62) 3.76 (1.21, 11.71) 0.02
rs2146323 Intron 2 CC 1 1  
    CA 1.46 (0.86, 2.47) 1.31 (0.73, 2.35) 0.37
    AA 2.43 (0.97, 6.08) 2.25 (0.81, 6.29) 0.12
rs3025021 Intron 6 TT 1 1  
    CT 0.54 (0.30, 0.97) 0.50 (0.11, 2.27) 0.37
    CC 0.59 (0.16, 2.17) 1.08 (0.26, 4.44) 0.92

Multiple logistic regression analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI) by comparing diabetic retinopathy (DR) group with diabetic without retinopathy (DWR) group. Adjusted OR represents data after adjustment for covariates including the age of diabetic onset, high albuminuria, insulin use, glycosylated hemoglobin A1c, fasting plasma glucose, and creatinine.

Yang, Mol Vis 2011; 17:3088-3096. http://www.molvis.org/molvis/v17/a332

©2011 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535